Drugs / ADVM-022
ADVM-022
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03748784 | Nov 2018 → Jun 2022 | wet macular degeneration | Adverum Biotechnologies, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05536973 | Aug 2022 → Aug 2024 overdue | wet macular degeneration | Adverum Biotechnologies, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04418427 | May 2020 → Nov 2022 | diabetic macular edema | Adverum Biotechnologies, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADVM-022 | “We hypothesised that an in-office, intravitreal administration of ixoberogene soroparvovec (ixo-vec, formerly ADVM-022), a single-dose gene therapy encoding for the proven...” PMID 38152412 ↗ Dec 2023 |
| Known as | AAV.7m8-aflibercept | “ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product being developed for the treatment of nAMD” NCT05536973 ↗ |
| Known as | Ixo-vec | “We hypothesised that an in-office, intravitreal administration of ixoberogene soroparvovec (ixo-vec, formerly ADVM-022), a single-dose gene therapy encoding for the proven...” PMID 38152412 ↗ Dec 20231“ADVM-022 (also known as Ixo-vec and AAV.7m8-aflibercept) is an investigational gene therapy product developed for the treatment of serious retinal vascular diseases including...” NCT04418427 ↗ |
| Known as | ixoberogene soroparvovec | “We hypothesised that an in-office, intravitreal administration of ixoberogene soroparvovec (ixo-vec, formerly ADVM-022), a single-dose gene therapy encoding for the proven...” PMID 38152412 ↗ Dec 2023 |
| Modality | Gene therapy (AAV / viral vector) | “gene therapy product” NCT04418427 ↗ |
| Route | Intravitreal | “an in-office, intravitreal administration of ixoberogene soroparvovec” PMID 38152412 ↗ Dec 2023 |